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Abstract
Controlled release of a chemokine, stromal-cell-derived factor-1 (SDF-1), could be achieved with gelatin
hydrogels of release carrier. Gelatin was chemically derivatized to give it different electric charge and hy-
drophobicity. Among the derivatives, succinylated gelatin (Succ) of an anionic charge was the most suitable
for preparation of the hydrogel in terms of SDF-1 release. The time profile of SDF-1 release from the hy-
drogel of succinylated gelatin could be controlled by changing the water content of hydrogel which could
be modified by changing the conditions of hydrogel preparation. When evaluated after the subcutaneous
implantation of Succ hydrogels incorporating SDF-1 or injection of SDF-1 solution, significantly stronger
angiogenesis by the hydrogel was observed. The hydrogel implantation also enhanced the mRNA level of
SDF-1 receptor at the site implanted. It is possible that the gelatin hydrogel enabled SDF-1 to be released
locally, resulting in an enhanced angiogenesis at the site implanted.
© Koninklijke Brill NV, Leiden, 2010
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1. Introduction
As a new strategy to treat defective tissues, the therapy of regenerative medicine
by tissue engineering has been expected. In the concept of tissue engineering, cells
and the local environment, which is composed of scaffolds and bioactive mole-
cules, are combined to use for the natural induction of tissue regeneration [1]. We
have explored biodegradable gelatin hydrogels for the controlled release of bioac-
tive molecules, such as growth factors and plasmid DNAs, to enhance their in vivo
biological activities [2]. This release system is one of the drug-delivery system
technologies to prolong their in vivo half-life period and consequently enhance the
therapeutic efficacy at reduced injection doses. Some clinical trials of angiogene-
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sis therapy by the release technology of basic fibroblast growth factor (bFGF) have
been started in Japan to demonstrate the therapeutic feasibility [3].
A chemokine, stromal-cell-derived growth factor (SDF-1, CXCL12), is known as
a chemokine which functions in the inflammation reaction, leukocyte development,
and the maintenance and recruitment of stem cells [4–7]. Additionally, SDF-1 has
an inherent ability to mobilize hematopoietic stem cells with the receptor CXCR4
from the bone marrow [8].
In this study, the hydrogel release technology was applied to SDF-1 and the
biological potential was evaluated in terms of SDF-1-induced angiogenesis. Hydro-
gels were prepared from various gelatin derivatives with different physicochemical
properties to achieve the controlled release of SDF-1. Following the subcutaneous
implantation of gelatin hydrogels incorporating SDF-1 into the back of mice, an-
giogenesis was evaluated and compared with that of SDF-1 solution injection. We
examined the in vivo profiles of SDF-1 release from gelatin hydrogels with different
biodegradabilities.
2. Materials and Methods
2.1. Materials
Gelatin samples, prepared by an alkaline treatment of bovine bone collagen (iso-
electric point (IEP) = 5.0) and an acidic treatment of pig skin collagen (IEP = 9.0),
termed as the acidic type and basic type here, were kindly supplied by Nitta
Gelatin (Osaka, Japan). Recombinant human stromal-cell-derived factor-1 (SDF-1,
350-NS/CF) was obtained from R&D systems (Minneapolis, MN, USA). Na125I
(NEZ-033H, >12.95 GBq/ml) and N′-succinimidyl-3-(4-hydroxy-3,5-di[125I]iodo-
phenyl)propionate ([125I]Bolton–Hunter reagent, NEX-120H, 147 MBq/ml) were
purchased from Perkin-Elmer Life Sciences (Boston, MA, USA). Glutaraldehyde
(GA), glycine, and other chemicals were obtained from Wako (Osaka, Japan) and
used without further purification.
2.2. Preparation of Gelatin Derivatives with Various Isoelectric Points
Gelatin was chemically derivatized with succinic anhydride (Succ), decylamine
(C10), spermine (SM) and ethylenediamine (ED) with or without 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) of a catalyst to change
the electronic nature as previously described [9]. The IEP of derivatives was mea-
sured according to the method previously reported [10]. Briefly, 1 wt% of gelatin
derivative solution was applied for an ion exchange column packed with mixed
cationic (Dowex 50W-X8) and anionic (Dowex 1-X8) exchange resins at 40◦C and
the pH of elution solution was measured with a pH meter (D-22, Horiba, Kyoto,
Japan) at 40◦C.
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2.3. Preparation of Gelatin Hydrogels
An aqueous solution of 5 wt% each gelatin derivative was mixed with various
amounts of glutaraldehyde, followed by leaving at 4◦C for 12 h for gelatin cross-
linking. The cross-linked gelatin hydrogel was treated by 0.1 M glycine solution
to block the residual aldehyde groups. After washing with double-distilled water
(DDW) three times, the hydrogels were freeze-dried. The cross-linking extent of
hydrogels prepared was evaluated by measuring the water content according to the
method previously described [11].
2.4. In Vitro Release Test of SDF-1 from Gelatin Hydrogels
SDF-1 was radioiodinated through the conventional chloramine-T method as pre-
viously described [12]. Briefly, 5 µl of Na125I was added to 200 µl of SDF-1 solu-
tion in 0.5 M potassium phosphate buffer (pH 7.5) containing 0.5 M NaCl. Then,
0.2 mg/ml chloramine-T in the same buffer (100 µl) was added to the solution mix-
ture. After agitation at room temperature for 2 min, 100 µl of phosphate-buffered
saline (PBS) solution (pH 7.5) containing 0.4 mg sodium metabisulfate was added
to the reaction solution to stop the radioiodination. The reaction mixture was passed
through a PD-10 desalting column (GE Healthcare Life Sciences, Chalfont St Giles,
UK) to remove the uncoupled, free 125I molecules from the 125I-labeled SDF-1.
A PBS solution of 125I-labeled SDF-1 (20 µl) was dropped onto the freeze-dried
hydrogel of gelatin derivatives (2 mg, 2.5 × 2.5 × 3 mm3), followed by leaving at
25◦C for 3 h to obtain hydrogels incorporating 125I-labeled SDF-1. For the in vitro
release test, one hydrogel incorporating 125I-labeled SDF-1 was agitated at 37◦C in
1 ml PBS. The supernatant was removed 0.5, 1, 2, 4, 8 and 24 h later and replaced
with the same volume of fresh PBS. The radioactivity of each supernatant was mea-
sured on a gamma counter (ARC-301B, Aloka, Tokyo, Japan) to evaluate the time
profile of SDF-1 release (n = 3 at each time point).
2.5. In Vivo Release Test of SDF-1 from Gelatin Hydrogels
All the animal experiments were performed according to the Institutional Guidance
of Kyoto University on Animal Experimentation and under permission by animal
experiment committee of Institute for Frontier Medical Science, Kyoto University.
All the surgical and observation procedures were performed under continuous in-
halation anesthesia by isoflurane (Forane®, Abbott Japan, Osaka, Japan) with 400
units of anesthesia (Univentor, Zejtun, Malta). PBS containing 125I-labeled SDF-1
(20 µl) was dropped onto 2 mg of freeze-dried gelatin hydrogels, followed by
incubation at 25◦C for 3 h to allow to swell into the hydrogel. Following the implan-
tation of gelatin hydrogels incorporating 125I-labeled SDF-1 into the back subcutis
of female ddY mice, 6 weeks old (18–20 g body weight, Shimizu Laboratory Sup-
ply, Kyoto, Japan), tissue around the site implanted was extracted at different time
intervals after hydrogel implantation, and the tissue radioactivity was counted by
the gamma counter to estimate the in vivo time profiles of SDF-1 release (n = 3 at
each time point).
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2.6. In Vivo Evaluation of Gelatin Hydrogel Degradation
To evaluate the degradation profiles of gelatin hydrogels, the in vivo implantation
of 125I-labeled hydrogels was performed according to the method previously re-
ported [12, 13]. Briefly, [125I]Bolton–Hunter reagent solution (20 µl) in benzene
was completely evaporated under dry nitrogen. The resultant reagent was dissolved
into 1 ml of PBS (pH 7.5). The reagent solution was impregnated into the gelatin
hydrogel sheet (2.5 × 2.5 × 3 mm3) at a volume of 20 µl per sheet. The sheets were
incubated at 4◦C for 3 h to introduce 125I into the amino groups of gelatin. The
radioiodinated sheets were washed with DDW thoroughly (4◦C, 4 days) to exclude
non-reacted 125I reagent, till the radioactivity of DDW returned to a background
level. 125I-labeled gelatin hydrogels were implanted into the back subcutis of mice.
Then, tissue around the sites implanted was extracted at different time intervals af-
ter hydrogel implantation, and the tissue radioactivity was counted by the gamma
counter to obtain the degradation profiles of hydrogels over time (n = 3 at each time
point).
2.7. RT-PCR Measurement
After implantation of SDF-1-incorporated gelatin hydrogels into the back subcutis,
15 × 15 mm2 of skin tissue around the site implanted was taken out with a surgical
scalpel. The total RNA was extracted by using RNeasy fibrous tissue mini kit (Qi-
agen, Valencia, CA, USA) according to the manufacturers’ instructions. Reverse
transcription reaction was performed with the SuperScript II First-Stand Synthe-
sis System (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed on a
Prism 7500 real time PCR thermal cycler (Applied Biosystems, Foster City, CA,
USA) from 10 ng of cDNA in a total volume of 25 µl containing Power SYBR
Green PCR Master Mix (Applied Biosystems) and 10 µM of each primer (Ta-
ble 1). The reaction mixture was incubated for the initial denaturation at 95◦C
for 10 min, followed by 40 PCR cycles. Each cycle consisted of the following
three steps; 94◦C for 15 s, 57◦C for 15 s and 72◦C for 1 min. Each mRNA level
was normalized by the expression level of 18S ribosomal RNA as an internal con-
trol.
Table 1.
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2.8. Angiogenesis Assay of Gelatin Hydrogels Incorporating SDF-1
The biological activity of SDF-1 incorporated in gelatin hydrogels was evaluated
by using a skinfold chamber attached on the back skin of mice, according to the
study by Ichioka et al. [14]. The gelatin hydrogel incorporating 5 µg of SDF-1 was
implanted into the skin defect in the chamber 3 days after the chamber attachment.
The number of capillaries newly-formed around the hydrogel implanted was micro-
scopically counted at different time intervals using a Stemi 2000C stereomicroscope
(Carl Zeiss Japan, Tokyo, Japan).
2.9. Statistical Analysis
All the results were expressed as the mean ± standard deviation. For statistical
analysis, the Tukey–Kramer post-test for multiple comparisons was used and dif-
ferences were considered to be significant at P < 0.05.
3. Results
3.1. Characterization of Gelatin Derivatives and Their Hydrogels
Table 2 shows the isoelectric point and degree of introduction of gelatin derivatives
prepared, and the water content of their hydrogels cross-linked with glutaraldehyde.
pI5 and pI9 gelatin were alkaline and acid-processed gelatin raw materials. Thus,
the degree of introduction was not indicated. Succinylation of gelatin decreased
the IEP while the derivatization with spermine and ethylenediamine increased it.
Chemical derivatization modified the electric charge of gelatin. For in vitro and in
vivo release experiment, hydrogels from gelatin derivatives with water contents of
97–98% were used. Table 3 shows the water content of hydrogels prepared from
succinylated gelatin. The water content was changed by altering the GA concentra-
tion in hydrogel preparation.
Table 2.
Isoelectric points and degree of introduction of gelatin derivatives used for hydrogel preparation, and
water contents of the hydrogels cross-linked with glutaraldehyde
Succ C10 pI5 pI9 SM ED
IEP 4.57 4.72 5.09 8.90 10.83 11.21
Degree of 29.0 ± 1.2 28.6 ± 2.4 – – 49.0 ± 1.1 50.9 ± 1.1
introduction
(mol/mol%)
The water content 97.9 ± 0.0 97.4 ± 0.2 97.8 ± 0.2 98.2 ± 0.1 97.4 ± 0.8 97.9 ± 0.6
of hydrogels
(wt%)
Succ, succinylated gelatin; C10, decylamine-introduced gelatin; pI5, acidic type gelatin; pI9, basic
type gelatin; SM, spermine-introduced gelatin; ED, ethylenediamine-introduced gelatin.
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Table 3.
Preparation conditions and water content of succinylated gelatin hydrogels
Gelatin (wt%) Glutaraldehyde (mM) Water content (wt%)
5 44.9 95.8 ± 0.1
5 22.4 96.3 ± 0.1
5 11.2 97.9 ± 0.0
5 6.24 98.8 ± 0.1
Figure 1. In vitro release profiles of SDF-1 from hydrogels of gelatin-derivatives; succinylated gelatin
(Succ) (!), decylamine-introduced gelatin (C10) (P), acidic type gelatin (pI5) (1), basic type gelatin
(pI9) ("), spermine-introduced gelatin (SM) (Q) and ethylenediamine-introduced gelatin (ED) (2).
Figure 1 shows the time profile of SDF-1 release from various gelatin hydrogels.
The release profiles depended on the type of gelatin hydrogels. Irrespective of the
hydrogel type, the amount of SDF-1 released from the gelatin hydrogels reached
to a certain level and saturated. Higher suppression of in vitro SDF-1 release was
observed for the hydrogel of Succ. Figure 2 shows the effect of hydrogel type on
the SDF-1 release. The highest amount of SDF-1 remaining was observed for the
Succ hydrogel.
3.2. In Vivo Profiles of SDF-1 Release and Gelatin Hydrogel Degradation
Figure 3 shows the time profiles of in vivo radioactivity remaining after implan-
tation of Succ gelatin hydrogels incorporating 125I-labeled SDF-1 with different
water contents. For the hydrogel incorporating 125I-labeled SDF-1, the radioactiv-
ity was retained for longer time periods than the solution of 125I-labeled SDF-1. The
radioactivity of every hydrogel decreased with the implantation time. The gelatin
Y. Kimura, Y. Tabata / Journal of Biomaterials Science 21 (2010) 37–51 43
Figure 2. Percent radioactivity remaining of gelatin hydrogels incorporating 125I-labeled SDF-1 24 h
after subcutaneous implantation. Abbreviations on the x-axis are as given in the legend to Fig. 1.
Figure 3. Time profiles of radioactivity remaining after subcutaneous implantation of 125I-labeled
SDF-1-incorporating gelatin hydrogels with different water contents of 95.8 (!), 96.3 (P), 97.9 (1)
and 98.8 wt% (") or subcutaneous injection of 125I-labeled SDF-1 solution (Q).
hydrogels with higher water content released SDF-1 faster than those with lower
water content. Figure 4 shows the time profiles of in vivo radioactivity remaining
after implantation of 125I-labeled gelatin hydrogels with different water contents.
Similar to Fig. 3, the gelatin hydrogels with higher water contents degraded faster
than those with lower water contents. Figure 5 shows the correlation of radioac-
tivity remaining after implantation between the gelatin hydrogels incorporating
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Figure 4. Time profiles of radioactivity remaining after subcutaneous implantation of 125I-labeled
gelatin hydrogels with different water contents of 95.8 (!), 96.3 (P), 97.9 (1) and 98.8 wt% (").
Figure 5. Relationship of remaining radioactivity after subcutaneous implantation into the mouse back
between 125I-labeled SDF-1 incorporated in gelatin hydrogels and 125I-labeled hydrogels of release
carrier.
125I-labeled SDF-1 and 125I-labeled gelatin hydrogels. The time profile of SDF-1
remaining was in good accordance with that of hydrogel remaining.
3.3. Angiogenesis by Gelatin Hydrogels Incorporating SDF-1
Figure 6 shows the mRNA expression of CXCR4, the receptor of SDF-1, around the
implanted sites of gelatin hydrogels incorporating various amounts of SDF-1. The
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Figure 6. CXCR4 mRNA expression at the implanted site of gelatin hydrogels (water content
98.8 wt%) incorporating various amounts of SDF-1 3 days after implantation. As control, mRNA
expression was examined after injection of SDF-1 solution (5 µg) (inj). ∗P < 0.05, significant against
the expression level of other groups.
expression level was up-regulated with the dose of SDF-1 implanted in the range of
low doses. The level was significantly high at the dose of 5 µg/site compared with
that of other doses.
Figure 7 shows the light microscopic photographs of the tissue site 3 days af-
ter implantation of gelatin hydrogel incorporating SDF-1. Figure 8 shows the time
profiles of the number of blood vessel capillaries newly formed at the tissue site
after implantation of gelatin hydrogels incorporating SDF-1. Significantly larger
number of capillaries was observed at the site implanted with the hydrogel incorpo-
rating SDF-1 4 and 7 days after implantation than the case of the SDF-1 injection
group. However, no significance in the capillary number was observed among all
the experimental groups 10 days after treatment.
4. Discussion
This study clearly demonstrates that the controlled release of SDF-1 could be
achieved by gelatin hydrogels. The SDF-1 release was experimentally confirmed
to be effective in enhancing SDF-1-induced angiogenesis. The Succ hydrogel was
suitable for SDF-1 release. The SDF-1 release enhanced the in vivo angiogenic ac-
tivity to a significantly great extent compared with the SDF-1 solution.
SDF-1 is of positive charge at physiological pH (pH 7.4) because of its IEP of
10.26. It is possible that SDF-1 molecules can electrostatically interact with the
succinylated gelatin of negative charge, resulting in the suppressed SDF-1 release
from the succinylated hydrogel accompanied with biodegradation. This hydrogel
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(a) (b)
(c)
Figure 7. Light microscopic photographs of tissue site 3 days after implantation of gelatin hydrogel
(water content 98.8 wt%) incorporating 5 µg SDF-1 (a) and empty gelatin hydrogel (b) or injection of
SDF-1 solution (5 µg) (c). Scale bar = 1 mm. This figure is published in colour in the online edition
of this journal that can be accessed via http://www.brill.nl/jbs
degradation-based SDF-1 release is experimentally confirmed by the in vitro and
in vivo tests of SDF-1 release (Figs 1 and 2). Irrespective of the hydrogel type,
the amount of SDF-1 released in vitro from gelatin hydrogels increased with time
to attain a certain level and thereafter saturated. In this release system, the SDF-1
molecules are immobilized in the hydrogel through their physicochemical inter-
action with the hydrogel gelatin. Without the enzymatic degradation of hydrogels
to generate water-soluble gelatin fragments, SDF-1 molecules immobilized are not
released from the hydrogels. Based on this release mechanism, not all the SDF-1
molecules are released under the in vitro conditions in the absence of enzymes
where the hydrogel is not degraded. The initial release of SDF-1 is due to the sim-
ple diffusion of free SDF-1 non-immobilized in the hydrogel. This release profile
was identical with that of other growth factors reported previously [9, 15]. The
SDF-1-gelatin interaction would suppress the SDF-1 release from the hydrogel un-
der the in vitro condition where the hydrogel is not degraded. Such a suppressed
effect, although low, was observed for other types of hydrogels under the in vitro
condition where the hydrogel is not degraded. This can be explained by different
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Figure 8. The number of blood vessel capillaries newly formed at the tissue site at different time
intervals after implantation of gelatin hydrogels (water content 98.8 wt%) incorporating 5 of SDF-1
(!) and empty gelatin hydrogels (P) or injection of SDF-1 solution (5 µg) (1). ∗P < 0.05, significant
against the capillary number of SDF-1 solution group, †P < 0.05, significant against the capillary
number of empty gelatin hydrogel group.
interaction forces between SDF-1 and gelatin molecules. In addition to the electro-
static interaction there are hydrophobic and hydrogen bonding interactions between
SDF-1 and gelatin molecules. In the case of basic fibroblast growth factor (bFGF)
of positive charge, the electrostatic interaction mainly plays an important role in
the bFGF immobilization into the hydrogel for the release [15]. Since the SDF-1
molecule has an electric nature similar to bFGF, it is conceivable that the elec-
trostatic interaction with gelatin is prominent for the SDF-1 release. The in vitro
(Fig. 1) and in vivo (Fig. 2) conditions affect the release profile of SDF-1. In the
former, since PBS does not contain any enzymes to degrade the hydrogel, only the
SDF-1 molecules in the free form can be released from the hydrogel. On the other
hand, in the in vivo system, there are many enzymes and proteins. It is likely that
upon degrading the hydrogel, the SDF-1 immobilized can be solubilized in water,
resulting in the release from the hydrogel. Generally considering that the longer
SDF-1 release results in the higher angiogenesis in vivo, in this study it is practi-
cally reasonable to take the hydrogel system which can release in vivo for longer
time periods. Based on this point, the succinylated gelatin hydrogel was used for
in vivo angiogenic experiment. The cross-linking extent of succinylated gelatin hy-
drogels was changed by the preparation conditions (Table 3) and the time profiles
of SDF-1 release and hydrogels degradation were greatly influenced by the cross-
linking extent of hydrogels (Figs 3 and 4). When estimated the cross-link density of
hydrogels prepared (average water content 95.8, 96.3, 97.9 and 98.8 wt%) based on
the Flory swelling equation [16] was 58, 42, 11 and 3.2 × 10−7/cm3, respectively.
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On the other hand, the molecular size of SDF-1 dimer is reported to be smaller than
7.1 nm in diameter [17]. Since the size is small enough compared with the network
of hydrogels calculated from the cross-linking density, we can say that a free SDF-1
molecule can easily pass through the water phase in hydrogel. Taken together, if
the SDF-1 does not interact with the succinylated gelatin, it would be rapidly re-
leased from the hydrogel. When the percent remaining of SDF-1 was compared, it
tended to become higher with a decrease in the water content of hydrogels. This
finding can be explained in terms of cross-linking extent by glutaraldehyde. The
cross-linking reaction decreased the amino groups of gelatin and, consequently, the
COOH/NH2 ratio of gelatin would become larger. It is possible that the increased
negative charge increase the interaction degree between the SDF-1 and gelatin, re-
sulting in increased percent remaining of SDF-1.
A good correlation of the in vivo time profile between the SDF-1 release and
hydrogel degradation (Fig. 5) clearly indicates that the SDF-1 release was not gov-
erned by the simple diffusion mechanism of SDF-1, but by the degradation of
gelatin hydrogel. This phenomenon was identical with that of bFGF release reported
previously [18]. Taken together, we could be confirmed that SDF-1 was released by
weakening electrostatic interaction following release carrier degradation.
CXCR4 is an inherent receptor of SDF-1, which is expressed on hematopoi-
etic cells, vascular endothelial cells and mesenchymal stem cells [6, 19–24]. In
Fig. 6, the mRNA expression around the implantation site of gelatin hydrogels in-
corporating SDF-1 was increased. The expression level compared with that of the
positive control (thymus tissue) was depended on the SDF-1 implantation dose and
the highest expression was observed at the dose of 5 µg. Taken together, it is highly
possible that the implantation of SDF-1-incorporated gelatin hydrogels enhanced
the accumulation of CXCR4 positive cells around the site implanted, resulting in
the enhanced formation of capillary (Figs 7 and 8). Salcedo et al. [25] reported
that angiogenesis was detected in mice after the local daily subcutaneous injec-
tion of 1 µg SDF-1 four times. However, the effective threshold dose of SDF-1 to
induce angiogenesis is still unknown. There are other reports that 60 or 100 ng of
SDF-1 dose was good for cell accumulation [26] or treatment of myocardiac infarc-
tion [27]. Further experiments are needed to determine the optimal dose of SDF-1
implanted. In the range of lower SDF-1 doses, the level of CXCR4-positive cells
accumulated around the implanted site decreased with the dose, but higher SDF-1
doses decreased the level (Fig. 6). This phenomenon can be explained in terms of
the SDF-1 receptor down-regulation. Generally, the chemokine action decreased
when the dose is too high because of the down-regulation of the receptor [28].
An appropriate amount of SDF-1 released from the hydrogel would be effective in
the mobilization of CXCR4-positive cells and consequently angiogenesis enhance-
ment.
The in vivo angiogenic assay showed that faster and stronger formation of new
capillaries was detected for the hydrogel incorporating SDF-1 than for the empty
hydrogel and SDF-1 solution. We used succinylated gelatin hydrogel incorporating
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SDF-1 for the angiogenic assay in terms of positive cell accumulation of the re-
ceptor, CXCR4, because the maximum amount of SDF-1 remaining was observed
after subcutaneous implantation with the hydrogel. It is possible that the gelatin
hydrogel enabled SDF-1 to be released locally in a controlled manner, resulting in
an enhanced recruitment of cells for angiogenesis (Figs 7 and 8). A significantly
higher number of capillaries formed newly was observed for the gelatin incorporat-
ing SDF-1 4 and 7 days after implantation than in the case of the SDF-1 injection
group. In addition, the mean number of capillaries seems to decrease for the gelatin
incorporating SDF-1 10 days after treatment. However, no significanct difference
in the capillary number was observed among all the experimental groups 10 days
after treatment. These phenomena were also observed in the study previously re-
ported from Ichioka et al. [14]. It is known that necessary mediators are secreted to
initiate and promote the wound repair process at normal murine skin after creation
of defect. SDF-1 is also reported to express in the inflammation stage [29, 30]. It
could be thought that the normal wound repair process was accelerated by the im-
plantation of gelatin hydrogels incorporating SDF-1. We believe that this strongly
indicates feasibilities of the SDF-1-incorporated hydrogel in angiogenic induction.
Many researchers have been reported on angiogenesis using vascular endothelial
growth factor, FGF family, and other growth factors or chemokines [31–33]. It has
been known that SDF-1 is induced by factors such as VEGF or bFGF, and plays
an important role as a factor to recruit bone marrow-derived circulating cells [25,
34]. Considering the inherent nature of SDF-1, it is no doubt that the controlled
release of SDF-1 is a promising strategy to induce angiogenesis by making use of
the natural healing potential of the living body.
There are several reports about the controlled release of SDF-1. Schantz et al.
[26] examined the homing of mesenchymal stem cells by SDF-1 treatment with
an infusion pump in vivo. The combination of vascular endothelial growth factor,
SDF-1, and bone morphogenetic protein-6 (60 ng each/10 days infusion) was effec-
tive in inducing vascularization into a poly(caprolactone) scaffold. Zhang et al. [27]
reported the controlled release of SDF-1 from poly(ethylene glycol)-conjugated fib-
rin and the therapeutic effect with a myocardial infarction model. SDF-1 could be
released from the fibrin matrix up to 10 days and the SDF-1 release could improve
the symptom of acute myocardial infarction through an enhanced homing of c-kit+
cells. Hiasa et al. reported the gene expression of SDF-1 by an electroporation
method with the plasmid DNA at the site of myocardiac infarction [35]. The SDF-1
protein was expressed up to 14 days in the muscle and the good therapeutic efficacy
resulted from the mobilization of endothelial progenitor cells into the infarction
site. The effective use of SDF-1 enhances the recruitment of key cells into the site
necessary, resulting in the cells-based enhancement of angiogenesis thereat. To this
end, it is necessary to develop a system for enhanced biological activity of SDF-1 in
vivo. For tissue engineering and regenerative medicine therapy, minimally invasive
and low-risk treatments should be required and developed. For our release system,
only a single implantation of biodegradable hydrogel could enhance the natural
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healing potential of the body, and consequently assist positively the healing process
of diseases. The release profiles of SDF-1 could be easily modified by changing the
cross-linking extent of the hydrogels (Fig. 4). The SDF-1 release technology will
be available to treat other diseases. The combination with other therapeutic agents
is another strategy to enhance the therapeutic efficacy of tissue regeneration.
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